Fred Alger Management LLC Has $36,000 Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Fred Alger Management LLC reduced its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 99.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,262 shares of the company's stock after selling 1,186,614 shares during the quarter. Fred Alger Management LLC's holdings in Autolus Therapeutics were worth $36,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AUTL. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics in the 4th quarter valued at $322,000. Bellevue Group AG acquired a new position in shares of Autolus Therapeutics during the fourth quarter worth approximately $322,000. Sierra Summit Advisors LLC bought a new stake in shares of Autolus Therapeutics during the fourth quarter valued at approximately $275,000. Perceptive Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $11,793,000. Finally, Perpetual Ltd raised its position in Autolus Therapeutics by 8.2% in the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company's stock worth $14,256,000 after purchasing an additional 169,784 shares during the last quarter. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Trading Up 4.3 %

NASDAQ AUTL traded up $0.15 on Friday, reaching $3.63. The company had a trading volume of 572,234 shares, compared to its average volume of 1,388,799. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. Autolus Therapeutics plc has a 52 week low of $2.01 and a 52 week high of $7.45. The stock has a market cap of $965.71 million, a price-to-earnings ratio of -3.03 and a beta of 2.05. The stock's 50 day moving average is $4.00 and its 200-day moving average is $4.33.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). Equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AUTL shares. Needham & Company LLC restated a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair reaffirmed an "outperform" rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Autolus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $8.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.